Novel antiplatelet therapies for treatment of patients with ischemic heart disease: Inhibitors of the platelet glycoprotein IIbIIIa integrin receptor

Colman, 1994, Overview of hemostasis, 3 Bennett, 1992, Mechanisms of platelet adhesion and aggregation: an up-date, Hosp Pract (Off Ed), 27, 124 Detwiler, 1978, Evidence that calcium regulates platelet function, Thromb Haemost, 40, 207, 10.1055/s-0038-1648653 Coller, 1987, Blood elements at surfaces: platelets, Ann N Y Acad Sci, 516, 362, 10.1111/j.1749-6632.1987.tb33056.x Hirsh, 1994, Overview of the thrombotic process and its therapy, 1151 Davies, 1994, Mechanisms of thrombosis in atherosclerosis, 1224 Faggiotto, 1984, Studies of hypercholesterolemia in the nonhuman primate: I. changes that lead to fatty streak formation, Arteriosclerosis, 4, 323, 10.1161/01.ATV.4.4.323 Richardson, 1989, Influence of plaque configuration and stress distribution of fissuring of coronary atherosclerotic plaques, Lancet, 2, 941, 10.1016/S0140-6736(89)90953-7 1989, Final report on the aspirin component of the ongoing Physician's Health Study, N Engl J Med, 321, 129, 10.1056/NEJM198907203210301 Lee, 1986, Correlation of coronary angioscopic to angiographic findings in coronary artery disease, Am J Cardiol, 58, 238, 10.1016/0002-9149(86)90054-8 Ip, 1994, Evolution, progression, and clinical manifestation of atherosclerosis, 1379 Frishman, 1986, Platelets and antiplatelet therapy in ischemic heart disease, Curr Probl Cardiol, 11, 73, 10.1016/0146-2806(86)90018-6 1995, 73 Moran, 1994, Mechanisms of action of antiplatelet drugs, 1623 1988, Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction, Lancet, 2, 349 Phillips, 1991, GPIIbIIIa: the responsive integrin, Cell, 65, 359, 10.1016/0092-8674(91)90451-4 Ikeda, 1991, The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress, J Clin Invest, 87, 1234, 10.1172/JCI115124 Charo, 1994, Platelet membrane glycoproteins, 489 Doolittle, 1979, The amino acid sequence of the α chain of human fibrinogen, Nature, 280, 464, 10.1038/280464a0 D'Souza, 1988, Localization of an arg-gly-asp recognition site within an integrin adhesion receptor, Science, 242, 91, 10.1126/science.3262922 Plow, 1992, Ligand binding to GPIIbIIIa: a status report, Semin Thromb Hemost, 18, 324, 10.1055/s-2007-1002571 Loftus, 1990, A β3 integrin mutation abolishes ligand binding and alters divalent cation-dependent conformation, Science, 249, 915, 10.1126/science.2392682 Newman, 1991, The molecular genetic basis of Glanzmann's thrombasthenia in the Iraqi-Jewish and Arab populations in Israel, 88, 3160 Coller, 1990, Platelets and thrombolytic therapy, N Engl J Med, 322, 33, 10.1056/NEJM199001043220107 Coller, 1986, Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIbIIIa receptor in an experimental animal model, Blood, 68, 783, 10.1182/blood.V68.3.783.783 Lefkovits, 1995, Platelet glycoprotein IIbIIIa receptors in cardiovascular medicine, N Engl J Med, 332, 1553, 10.1056/NEJM199506083322306 Schrör, 1995, Antiplatelet drugs, Drugs, 50, 7, 10.2165/00003495-199550010-00002 Shebuski, 1990, Acceleration of a recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the arg-gly-asp-containing peptide bitistatin in a canine model of coronary thrombosis, Circulation, 82, 169, 10.1161/01.CIR.82.1.169 Mellot, 1989, Effects of bitistatin, a snake venom peptide and platelet fibrinogen receptor antagonist in a canine model of thrombolysis and reocclusion, Circulation, 80, II Yasuda, 1991, Kistrin, a polypeptide GPIIbIIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation, Circulation, 83, 1038, 10.1161/01.CIR.83.3.1038 Scarborough, 1991, Barbourin: a GPIIbIIIa specific integrin antagonist from the venom of Sistrurus M. barbouri, J Biol Chem, 266, 9359, 10.1016/S0021-9258(18)92826-7 Coller, 1985, A new murine monoclonal antibody reports an activation dependent change in the conformation and/or microenvironment of the glycoprotein IIbIIIa complex, J Clin Invest, 76, 101, 10.1172/JCI111931 Kohler, 1975, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, 256, 495, 10.1038/256495a0 Faulds, 1994, Abciximab (c7E3 Fab): a review of its pharmacology and therapeutic potential in ischaemic heart disease, Drugs, 48, 683, 10.2165/00003495-199448040-00007 Coller, 1989, Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIbIIIa receptor, Circulation, 80, 1766, 10.1161/01.CIR.80.6.1766 Bates, 1991, A monoclonal antibody against the platelet glycoprotein IIbIIIa receptor complex prevents aggregation and thrombosis in a canine model of coronary angioplasty, Circulation, 84, 2463, 10.1161/01.CIR.84.6.2463 Sudo, 1994, Inhibition of platelet GPIIbIIIa receptor with monoclonal antibody [7E3-F(ab')2] prevents arterial, but not venous rethrombosis, Circulation, 90, 1 Folts, 1988, Epinephrine potentiation of in vivo stimuli reverses aspirin inhibition of platelet thrombus formation in stenosed canine coronary arteries, Thromb Res, 50, 507, 10.1016/0049-3848(88)90199-5 Gold, 1988, Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIbIIIa antibody in a canine preparation, Circulation, 77, 670, 10.1161/01.CIR.77.3.670 Mickelson, 1990, Antiplatelet antibody [7E3 F(ab')2) prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model, Circulation, 81, 617, 10.1161/01.CIR.81.2.617 Hanson, 1988, Effects of monoclonal antibodies against the platelet glycoprotein IIbIIIa complex on thrombosis and hemostasis in the baboon, J Clin Invest, 81, 149, 10.1172/JCI113286 Gold, 1990, Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIbIIIa in patients with unstable angina pectoris, J Clin Invest, 86, 651, 10.1172/JCI114757 Bhattacharya, 1991, Chimerization of monoclonal antibody 7E3 preserves the GPIIbIIIa receptor blockade and platelet functional inhibition of murine 7E3, Clin Res, 39, 196A Harrison, 1992, The influence of therapeutic blocking of GP IIbIIIa on platelet α-granular fibrinogen, Br J Haematol, 82, 721, 10.1111/j.1365-2141.1992.tb06950.x Christopoulos, 1993, Flow cytometric observations on the in vivo use of Fab fragments of a chimaeric monoclonal antibody to platelet glycoprotein IIb–IIIa, Blood Coagul Fibrinolysis, 4, 729, 10.1097/00001721-199304050-00009 Tcheng, 1991, Chimeric antiplatelet GPIIbIIIa receptor antibody (c-7E3) in elective PTCA: safety and platelet function inhibition, Circulation, 84, II Sweeny, 1993, Infusion of a chimeric monoclonal Fab fragment (c7E3) against platelet glycoprotein IIb–IIIa potently inhibits platelet aggregation but does not affect in vivo platelet survival, J Am Coll Cardiol, 21, 253A Wills, 1990, Clinical pharmacokinetics of interferons, Clin Pharmacokinet, 19, 390, 10.2165/00003088-199019050-00003 Simoons, 1994, Randomized trial of IIbIIIa platelet receptor blocker in refractory unstable angina, Circulation, 89, 596, 10.1161/01.CIR.89.2.596 Kaplan, 1991, Boles of thrombin and platelet membrane glycoprotein IIbIIIa in platelet-subendothelial deposition after angioplasty in an ex vivo whole artery model, Circulation, 84, 1279, 10.1161/01.CIR.84.3.1279 Tcheng, 1994, Pharmacodynamics of chimeric glycoprotein IIbIIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty, Circulation, 90, 1757, 10.1161/01.CIR.90.4.1757 EPIC Investigators, 1994, Use of a monoclonal antibody directed against the platelet glycoprotein IIbIIIa receptor in high-risk coronary angioplasty, N Engl J Med, 330, 956, 10.1056/NEJM199404073301402 Topol, 1994, Randomized trial of coronary intervention with antibody against platelet IIbIIIa integrin for reduction of clinical restenosis; results at six months, Lancet, 343, 881, 10.1016/S0140-6736(94)90007-8 Matsuno, 1994, Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointimal formation, Circulation, 90, 2203, 10.1161/01.CIR.90.5.2203 Kouns, 1992, Reversible conformational changes induced in glycoprotein IIbIIIa by a potent and selective peptidomimetic inhibitor, Blood, 80, 2539, 10.1182/blood.V80.10.2539.2539 Nichols, 1992, Development of GPIIbIIIa antagonists as antithrombotic drugs, Trends Pharmacol Sci, 13, 413, 10.1016/0165-6147(92)90126-Q Mousa, 1994, Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIbIIIa receptor antagonist, Circulation, 89, 3, 10.1161/01.CIR.89.1.3 Charo, 1992, Pharamcodynamics of the GPIIbIIIa antagonist integrelin: phase I clinical studies in normal healthy volunteers, Circulation, 86, I Harrington, 1994, Profound, sustained and reversible platelet inhibition following administration of a glycoprotein IIbIIIa inhibitor with and without heparin in patients with unstable angina, Circulation, 90, I Nicolini, 1994, Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis, Circulation, 89, 1802, 10.1161/01.CIR.89.4.1802 Tcheng, 1993, Outcome of patients treated with the GPIIbIIIa inhibitor integrelin during coronary angioplasty: results of the IMPACT study, Circulation, 88, I Nicholson, 1995, SC-54684A: an orally active inhibitor of platelet aggregation, Circulation, 91, 403, 10.1161/01.CIR.91.2.403 Szalony, 1995, Extended inhibition of platelet aggregation with an orally active platelet inhibitor SC-54684A, Circulation, 91, 411, 10.1161/01.CIR.91.2.411 Satoh, 1993, Tetrafibricin: a non-peptide fibrinogen receptor inhibitor from Streptomyces neyagawaensis—II. its antiplatelet activities, Thromb Res, 72, 401, 10.1016/0049-3848(93)90240-O Peerlinck, 1993, MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIbIIIa antagonist, is active in man, Circulation, 88, 1512, 10.1161/01.CIR.88.4.1512 Kereiakes, 1994, A dosing study in high-risk PTCA of MK-383, a platelet IIbIIIa antagonist, Circulation, 90, I Theroux, 1994, A randomized double-blind controlled trial with the non-peptidic platelet GP IIbIIIa antagonist RO 44-9883 in unstable angina, Circulation, 90, I Barrett, 1994, Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein IIbIIIa receptor antagonist, in healthy men, Clin Pharmacol Ther, 56, 377, 10.1038/clpt.1994.152 Theroux, 1994, A heparin-controlled study of MK-383 in unstable angina, Circulation, 90, I